185 related articles for article (PubMed ID: 28657833)
1. Serum interleukin-6 and survivin levels predict clinical response to etanercept treatment in patients with established rheumatoid arthritis.
Shi R; Chen M; Litifu B
Mod Rheumatol; 2018 Jan; 28(1):126-132. PubMed ID: 28657833
[TBL] [Abstract][Full Text] [Related]
2. IL-1β, IL-17A, CRP and biologics history might serve as potential markers for clinical response to etanercept in rheumatoid arthritis patients.
Zhang B; Jiang W
Inflammopharmacology; 2019 Dec; 27(6):1123-1130. PubMed ID: 31463666
[TBL] [Abstract][Full Text] [Related]
3. Niclosamide as an adjuvant to etanercept in treatment patients with active rheumatoid arthritis: an 8-week randomized controlled pilot study.
Al-Gareeb AIA; Gorial FI; Mahmood AS
Clin Rheumatol; 2018 Oct; 37(10):2633-2641. PubMed ID: 29882203
[TBL] [Abstract][Full Text] [Related]
4. Baseline CXCL10 and CXCL13 levels are predictive biomarkers for tumor necrosis factor inhibitor therapy in patients with moderate to severe rheumatoid arthritis: a pilot, prospective study.
Han BK; Kuzin I; Gaughan JP; Olsen NJ; Bottaro A
Arthritis Res Ther; 2016 Apr; 18():93. PubMed ID: 27102921
[TBL] [Abstract][Full Text] [Related]
5. Ex vivo inhibited cytokine profiling may explain inferior treatment response to golimumab after adalimumab failure in rheumatoid arthritis.
Tweehuysen L; Schraa K; Netea MG; van den Hoogen FHJ; Joosten LAB; den Broeder AA
Clin Exp Rheumatol; 2018; 36(1):140-143. PubMed ID: 29148425
[TBL] [Abstract][Full Text] [Related]
6. Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis.
Park MC; Chung SJ; Park YB; Lee SK
Scand J Rheumatol; 2008; 37(3):173-8. PubMed ID: 18465450
[TBL] [Abstract][Full Text] [Related]
7. Serum survivin predicts responses to treatment in active rheumatoid arthritis: a post hoc analysis from the SWEFOT trial.
Levitsky A; Erlandsson MC; van Vollenhoven RF; Bokarewa MI
BMC Med; 2015 Sep; 13():247. PubMed ID: 26420684
[TBL] [Abstract][Full Text] [Related]
8. Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity.
Inciarte-Mundo J; Ramirez J; Hernández MV; Ruiz-Esquide V; Cuervo A; Cabrera-Villalba SR; Pascal M; Yagüe J; Cañete JD; Sanmarti R
Arthritis Res Ther; 2016 Jul; 18(1):160. PubMed ID: 27391315
[TBL] [Abstract][Full Text] [Related]
9. Can baseline serum microRNAs predict response to TNF-alpha inhibitors in rheumatoid arthritis?
Cuppen BV; Rossato M; Fritsch-Stork RD; Concepcion AN; Schenk Y; Bijlsma JW; Radstake TR; Lafeber FP;
Arthritis Res Ther; 2016 Aug; 18(1):189. PubMed ID: 27558398
[TBL] [Abstract][Full Text] [Related]
10. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis.
Shimamoto K; Ito T; Ozaki Y; Amuro H; Tanaka A; Nishizawa T; Son Y; Inaba M; Nomura S
J Rheumatol; 2013 Jul; 40(7):1074-81. PubMed ID: 23637318
[TBL] [Abstract][Full Text] [Related]
11. Tumor necrosis factor blockade differentially affects innate inflammatory and Th17 cytokines in rheumatoid arthritis.
Zivojinovic SM; Pejnovic NN; Sefik-Bukilica MN; Kovacevic LV; Soldatovic II; Damjanov NS
J Rheumatol; 2012 Jan; 39(1):18-21. PubMed ID: 22133625
[TBL] [Abstract][Full Text] [Related]
12. Differential response of serum amyloid A to different therapies in early rheumatoid arthritis and its potential value as a disease activity biomarker.
Hwang YG; Balasubramani GK; Metes ID; Levesque MC; Bridges SL; Moreland LW
Arthritis Res Ther; 2016 May; 18(1):108. PubMed ID: 27188329
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-1β measurement in stimulated whole blood cultures is useful to predict response to anti-TNF therapies in rheumatoid arthritis.
Kayakabe K; Kuroiwa T; Sakurai N; Ikeuchi H; Kadiombo AT; Sakairi T; Kaneko Y; Maeshima A; Hiromura K; Nojima Y
Rheumatology (Oxford); 2012 Sep; 51(9):1639-43. PubMed ID: 22596214
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment Prediction of Individual Rheumatoid Arthritis Patients' Response to Anti-Cytokine Therapy Using Serum Cytokine/Chemokine/Soluble Receptor Biomarkers.
Uno K; Yoshizaki K; Iwahashi M; Yamana J; Yamana S; Tanigawa M; Yagi K
PLoS One; 2015; 10(7):e0132055. PubMed ID: 26176225
[TBL] [Abstract][Full Text] [Related]
15. Tumour necrosis factor-α/etanercept complexes in serum predict long-term efficacy of etanercept treatment in seronegative rheumatoid arthritis.
Berthold E; Månsson B; Gullstrand B; Geborek P; Saxne T; Bengtsson AA; Kahn R
Scand J Rheumatol; 2018 Jan; 47(1):22-26. PubMed ID: 28485187
[TBL] [Abstract][Full Text] [Related]
16. Etanercept concentration in patients with rheumatoid arthritis and its potential influence on treatment decisions: a pilot study.
Daïen CI; Daïen V; Parussini E; Dupuy AM; Combe B; Morel J
J Rheumatol; 2012 Aug; 39(8):1533-8. PubMed ID: 22753654
[TBL] [Abstract][Full Text] [Related]
17. Proinflammatory cytokines in monitoring the course of disease and effectiveness of treatment with etanercept (ETN) of children with oligo- and polyarticular juvenile idiopathic arthritis (JIA).
Kaminiarczyk-Pyzalka D; Adamczak K; Mikos H; Klimecka I; Moczko J; Niedziela M
Clin Lab; 2014; 60(9):1481-90. PubMed ID: 25291944
[TBL] [Abstract][Full Text] [Related]
18. IL-1β, IL-17A and combined phototherapy predicts higher while previous systemic biologic treatment predicts lower treatment response to etanercept in psoriasis patients.
Liu Y; Qin G; Meng Z; Du T; Wang X; Tang Y; Cao J
Inflammopharmacology; 2019 Feb; 27(1):57-66. PubMed ID: 30242748
[TBL] [Abstract][Full Text] [Related]
19. Infliximab and etanercept have distinct actions but similar effects on cytokine profiles in rheumatoid arthritis.
Takeshita M; Suzuki K; Kikuchi J; Izumi K; Kurasawa T; Yoshimoto K; Amano K; Takeuchi T
Cytokine; 2015 Oct; 75(2):222-7. PubMed ID: 26095743
[TBL] [Abstract][Full Text] [Related]
20. The immunomodulatory effects of TNF-α inhibitors on human Th17 cells via RORγt histone acetylation.
Lin YC; Lin YC; Wu CC; Huang MY; Tsai WC; Hung CH; Kuo PL
Oncotarget; 2017 Jan; 8(5):7559-7571. PubMed ID: 27926504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
